Ultra-high-frequency ultrasound monitoring of plaque psoriasis during ixekizumab treatment.
Anti-IL17
high-frequency ultrasound
ixekizumab
psoriasis
psoriasis treatments
ultrasonography
Journal
Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI)
ISSN: 1600-0846
Titre abrégé: Skin Res Technol
Pays: England
ID NLM: 9504453
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
07
04
2020
accepted:
04
06
2020
pubmed:
3
2
2021
medline:
19
8
2021
entrez:
2
2
2021
Statut:
ppublish
Résumé
High-frequency ultrasound (HFUS) is a non-invasive method that detects superficial skin features. Ultra-high frequencies (50-100 MHz) can reveal epidermis and dermis structures. In this study, we describe the psoriatic plaque using a new device equipped with a 70 MHz probe (VEVO We examined the superficial hyperechoic band, the subepidermal hypoechoic band (SLEB), and the vascularization of the plaque in ten patients affected by plaque psoriasis. The average superficial hyperechoic band thickness was 0.2157 mm before treatment, 0.1611 mm after 15 days, and 0.1354 mm (P < .05) after 30 days. The SLEB thickness was 0.7535 mm at baseline, 0.3300 mm after 15 days (P < .05), and 0.2007 mm (P < .05) after 30 days. The average percentage vascularization was 50.21% at baseline, 13.15% after 15 days (P < .05), and 5.97% after 30 days. UHFUS assessment highlighted the rapid action of the drug in terms of the decrease in vascularization after 15 days. It revealed a statistically significant reduction in SLEB thickness after 15 days and a significant reduction in the hyperechoic superficial band after 30 days. VEVO
Sections du résumé
BACKGROUND
BACKGROUND
High-frequency ultrasound (HFUS) is a non-invasive method that detects superficial skin features. Ultra-high frequencies (50-100 MHz) can reveal epidermis and dermis structures.
OBJECTIVES
OBJECTIVE
In this study, we describe the psoriatic plaque using a new device equipped with a 70 MHz probe (VEVO
METHODS
METHODS
We examined the superficial hyperechoic band, the subepidermal hypoechoic band (SLEB), and the vascularization of the plaque in ten patients affected by plaque psoriasis.
RESULTS
RESULTS
The average superficial hyperechoic band thickness was 0.2157 mm before treatment, 0.1611 mm after 15 days, and 0.1354 mm (P < .05) after 30 days. The SLEB thickness was 0.7535 mm at baseline, 0.3300 mm after 15 days (P < .05), and 0.2007 mm (P < .05) after 30 days. The average percentage vascularization was 50.21% at baseline, 13.15% after 15 days (P < .05), and 5.97% after 30 days. UHFUS assessment highlighted the rapid action of the drug in terms of the decrease in vascularization after 15 days. It revealed a statistically significant reduction in SLEB thickness after 15 days and a significant reduction in the hyperechoic superficial band after 30 days.
CONCLUSIONS
CONCLUSIONS
VEVO
Substances chimiques
Antibodies, Monoclonal, Humanized
0
ixekizumab
BTY153760O
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
277-282Informations de copyright
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Bhatta AK, Keyal U, Liu Y. Application of high frequency ultrasound in dermatology. Discov Med. 2018;26(145):237.A-242.A.
Wortsman X. Ultrasound in dermatology: why, how, and when? Semin Ultrasound CT MR. 2013;34(3):177-195.
Oranges T, Vitali S, Benincasa B, et al. Advanced evaluation of hidradenitis suppurativa with ultra- high frequency ultrasound: a promising tool for the diagnosis and monitoring of disease progression. Skin Res Technol. 2019;26(4):513-519.[Epub head of print].
Izzetti R, Vitali S, Oranges T, et al. Intraoral ultra-high frequency ultrasound study of oral lichen planus: a pictorial review. Skin Res Technol. 2020;26:200-204.
Izzetti R, Vitali S, Aringhieri G, et al. The efficacy of Ultra-High Frequency Ultrasonography in the diagnosis of intraoral lesions. Oral Surg Oral Med Oral Pathol Oral Radiol. 2019;129(4):401-410.[Epub head of print].
Rocken M, Schaller M, Sattler E. Color atlas of dermatology. Yale J Biol Med. 2012;85:430-431.
Papp KA, Leonardi C, Blauvelt A, et al. Efficacy of Ixekizumab therapy: integrated analysis of 3 double-blind, controlled trials (UNCOVER-1, UNCOVER-2, UNCOVER-3). Br J Dermatol. 2018;178(3):674-681.Epub 2018 Feb 23.
Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis-results of two phase 3 trials. N Engl J Med. 2014;371(4):326-338.Epub 2014 Jul 9.
Lebwohl M, Strober B, Menter A. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. N Engl J Med. 2015;373(14):1318-1328.
Lebwohl MG, Gordon KB, Gallo G, et al. Ixekizumab sustains high level of efficacy and favorable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER-3 study. JEADV. 2020;34:301-309.
Somlea MC, Boca AN, Pop AD, et al. High-frequency ultrasonography of psoriatic skin: a non-invasive technique in the evaluation of the entire skin of patients with psoriasis: a pilot study. Exp Ther Med. 2019;18:4981-4986.
El Gammal S, El Gammal C, Kaspar K, et al. Sonography of the skin at 100 MHz enables in vivo visualization of stratum corneum and viable epidermis in palmar skin and psoriatic plaques. J Invest Dermatol. 1999;113(5):821-829.
El Gammal S, Auer T, Popp C, et al. Psoriasis vulgaris in 50 MHz B-scan ultrasound: characteristic features of stratum corneum, epidermis and dermis. Acta Derm Venereol Suppl. 1994;186:173-176.
Di Nardo A, Seidenari S, Giannetti A. B-scanning evaluation with image analysis of psoriatic skin: a non-invasive technique to evaluate treatment of psoriasis. Int J Dermatol. 1994;33:786-790.
Micali G, Lacarruba F, Santagati C, Egan CG, Nasca MR, Musumeci ML. Linical, ultrasound and videodermatoscopy monitoring of psoriatic patients following biological treatment. Skin Res Technol. 2015;22:1-8.
Papp KA, Lebwohl MG. Onset of action of biologics in patients with moderate-to-severe psoriasis. J Drugs Dermatol. 2017;17(3):247-250.